In a retrospective study of sporadic metastatic colorectal cancer (mCRC), BRAF mutations, detected in 8% of patients, were emerged as an independent prognostic factor for both progression-free survival (PFS) and overall survival (OS) (Souglakos et al, 2009). This evidence concerns the gene BRAF and metastatic colorectal cancer.